^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MVT-1075

    i
    Other names: 177Lu Human Monoclonal Antibody 5B1, 177Lu-DTPA-HuMab-5B, MVT-1075, 177Lu-CHX-A"-DTPA-HuMab-5B1, MVT 1075
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    Ionizing radiation emitter, CA19-9 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075
    almost2years
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075
    3years
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2020 --> Dec 2021 | Active, not recruiting --> Suspended | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075